Onkologie 2020: 14(Suppl.C): 18-23 | DOI: 10.36290/xon.2020.051

Adverse effects of targeted cancer treatment

Miroslav Žiaran, Jindřich Kopecký
Klinika onkologie a radioterapie, Fakultní nemocnice Hradec Králové

Targeted therapy, along with immunotherapy, is considered one of the greatest advances in cancer treatment in the last decade. Its efficacy has changed the prognosis across oncology. The general mechanism of action of targeted therapy involves inhibition of aberrant signalling pathways that are responsible for tumour growth. However, given the fact that these signalling pathways are also present in healthy cells, potential adverse effects should be taken into account. The most frequent and most severe adverse effects encountered in oncological practice include dermal, vascular, gastrointestinal, cardiac and mucosal toxicity, as well as osteonecrosis of the jaw. The management of adverse effects associated with the administration of targeted therapy also involves raising patient awareness of anticipated treatment complications and of the ways of preventing them. The aim of this article is to present a coherent and concise overview of the most frequent adverse effects and their possible management.

Keywords: adverse effects, solid tumours, targeted therapy.

Published: June 2, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Žiaran M, Kopecký J. Adverse effects of targeted cancer treatment. Onkologie. 2020;14(Suppl.C):18-23. doi: 10.36290/xon.2020.051.
Download citation

References

  1. Lacouture ME, Maitland ML, Segaert S, et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer. 2010; 18(4): 509-522. Go to original source... Go to PubMed...
  2. Pomerantz RG, Mirvish ED, Geskin LJ. Cutaneous reactions to epidermal growth factor receptor inhibitors. J Drugs Dermatol. 2010; 9(10): 1229-1234. Go to PubMed...
  3. Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007; 13(13): 3913-3921. Go to original source...
  4. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010; 11(1): 21-28. Go to original source...
  5. Peeters M, Siena S, Van Cutsem E, et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer. 2009; 115(7): 1544-1554. Go to original source...
  6. Gutzmer R, Becker JC, Enk A, et al. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. J Dtsch Dermatol Ges. 2011; 9(3): 195-203. Go to original source...
  7. Tan EH, Chan A. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann Pharmacother. 2009; 43(10): 1658-1666. Go to original source... Go to PubMed...
  8. Scope A, Lieb JA, Dusza SW, et al. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol. 2009; 61(4): 614-620. Go to original source... Go to PubMed...
  9. Torino F, Corsello SM, Longo R, et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol. 2009; 6(4): 219-228. Go to original source... Go to PubMed...
  10. Mittal K, Wood LS, Rini BI. Axitinib in Metastatic Renal Cell Carcinoma. Biol Ther. 2012; 2: 5. Go to original source...
  11. Lucke C, Hoffken B, von zur Muhlen A. The effect of somatostatin on TSH levels in patients with primary hypothyroidism. J Clin Endocrinol Metab. 1975; 41(06): 1082-1084. Go to original source...
  12. de Groot JW, Zonnenberg BA, Plukker JT, et al. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther. 2005; 78(4): 433-438. Go to original source...
  13. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014; 24(12): 1670-1751. Go to original source... Go to PubMed...
  14. Izzedine H, Bahleda R, Khayat D, et al. Electrolyte disorders related to EGFR-targeting drugs. Crit Rev Oncol Hematol. 2010; 73(3): 213-219. Go to original source... Go to PubMed...
  15. Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol. 2007; 8(5): 387-394. Go to original source...
  16. Liamis G, Filippatos TD, Elisaf MS. Electrolyte disorders associated with the use of anticancer drugs. Eur J Pharmacol. 2016; 777: 78-87. Go to original source...
  17. Bhargava P. VEGF kinase inhibitors: how do they cause hypertension? Am J Physiol Regul Integr Comp Physiol. 2009; 297(1): R1-5. Go to original source...
  18. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009; 20(5): 807-815. Go to original source...
  19. Keefe DM, Bateman EH. Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol. 2011; 9(2): 98-109. Go to original source... Go to PubMed...
  20. Di Lisi D, Madonna R, Zito C, et al. Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. Int J Cardiol. 2017; 227: 11-17. Go to original source...
  21. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol. 2010; 7(10): 564-575. Go to original source... Go to PubMed...
  22. Eschenhagen T, Force T, Ewer MS, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011; 13(1): 1-10. Go to original source...
  23. Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018; 19(7): 904-915. Go to original source... Go to PubMed...
  24. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother. 2009; 43(3): 490-501. Go to original source... Go to PubMed...
  25. Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf. 2006; 5(4): 553-566. Go to original source...
  26. Elisei R, Schlumberger MJ, Muller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013; 31(29): 3639-3646. Go to original source...
  27. Frieling T, Heise J, Wassilew SW. Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib. Dtsch Med Wochenschr. 2009; 134(28-29): e1-2, 1464-1466. Go to original source...
  28. Hirsh V. Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol. 2011; 18(3): 126-138. Go to original source...
  29. Pessi MA, Zilembo N, Haspinger ER, et al. Targeted therapy-induced diarrhea: A review of the literature. Crit Rev Oncol Hematol. 2014; 90(2): 165-179. Go to original source... Go to PubMed...
  30. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007; 25(13): 1658-1664. Go to original source...
  31. Hirsh V, Blais N, Burkes R, et al. Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors. Curr Oncol. 2014; 21(6): 329-336. Go to original source...
  32. Benson AB, 3rd, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004; 22(14): 2918-2926. Go to original source... Go to PubMed...
  33. Karczmarek-Borowska B, Salek-Zan A. Hepatotoxicity of molecular targeted therapy. Contemp Oncol (Pozn). 2015; 19(2): 87-92. Go to original source... Go to PubMed...
  34. Teo YL, Ho HK, Chan A. Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis. Cancer Treat Rev. 2013; 39(2): 199-206. Go to original source...
  35. Vargas-Mendoza N, Madrigal-Santillán E, Morales-González A, et al. Hepatoprotective effect of silymarin. World J Hepatol. 2014; 6(3) :144-149. Go to original source...
  36. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009; 10(6): 559-568. Go to original source... Go to PubMed...
  37. Barber NA, Ganti AK. Pulmonary toxicities from targeted therapies: a review. Target Oncol. 2011; 6(4): 235-243. Go to original source... Go to PubMed...
  38. Cohen MH, Johnson JR, Chen YF, et al. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. 2005; 10(7): 461-466. Go to original source... Go to PubMed...
  39. Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol. 2018; 10: 1758835918793326. Go to original source... Go to PubMed...
  40. Santoni M, Rizzo M, Burattini L, et al. Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicity. Recent Pat Antiinfect Drug Discov. 2012; 7(2): 104-110. Go to original source...
  41. Hinchy NV, Jayaprakash V, Rossitto RA, et al. Osteonecrosis of the jaw - prevention and treatment strategies for oral health professionals. Oral Oncol. 2013; 49(9): 878-886. Go to original source...
  42. Shameem R, Lacouture M, Wu S. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients. Cancer Invest. 2015; 33(3): 70-77. Go to original source...
  43. Abdel-Rahman O, ElHalawani H, Ahmed H, et al. Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2015; 9(11): 1433-1445. Go to original source...
  44. Yuan A, Kurtz SL, Barysauskas CM, et al. Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors. Oral Oncol. 2015; 51(11): 1026-1033. Go to original source...
  45. Janelsins MC, Tejani MA, Kamen C, et al. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother. 2013; 14(6): 757-766. Go to original source... Go to PubMed...
  46. Larkin JM, Pyle LM, Gore ME. Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies. Oncologist. 2010; 15(11): 1135-1146. Go to original source... Go to PubMed...
  47. Vardy JL, Dhillon HM, Pond GR, et al. Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study. Ann Oncol. 2016; 27(9): 1761-1767. Go to original source...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.